Hormones and Agents Affecting Hormonal Mechanism : Androgens, Antiandrogens and Related Agents
INEBI1“Nebido Solution For Injection” 1000 mg/4ml; 4 ml/amp
OANDR2 “Andriol Testocaps Capsules” 40 mg/cap
TANDR1 “Androgel gel” 1%; 5 g/pkg
適應症：
INEBI1：治療原發性及繼發性65歲以下男性性腺機能低下症雄性素取代療法。
OANDR2：男性機能減退、男性更年期障礙。
TANDR1：經臨床徵象及實驗室檢驗確認，因睪固酮缺乏之男性生殖腺功能不足症的替代療法。
Usual dose:
Hypogonadism: topical (for the skin). Initial, 5 g (delivering 50 mg testosterone) applied qd (preferably in the morning) to clean, dry, intact skin of the shoulders and upper arms and/or abdomen; do not apply to genitals; may increase dose to 10 g after 2 wks as instructed by physician.
Replacement therapy (males): oral capsule. initially 120 to 160 mg daily in 2 divided doses for 2 to 3 weeks; adjust according to individual response and/or testosterone levels; usual maintenance dose: 40 to 120 mg daily (in divided doses)
Dose adjustment:
Geriatric: refer to adult dosing.
Renal Impairment : no dosage adjustments
Hepatic Impairment : no dosage adjustments
Contraindication: Breast carcinoma, Pregnancy, nursing, or women of childbearing potential.
Precaution: Serious pulmonary oil microembolism (POME) reactions, heart attack, stroke, or death.
Adverse effect:
Common: Acne, Injection site pain, Increased estradiol level, Increased hemoglobin, Insomnia, Irritability, Mood swings, Hypogonadism, Raised prostate specific antigen, Fatigue
Serious: Deep venous thrombosis, Erythrocytosis, Hematocrit – PCV, Prostate cancer, Pulmonary embolism, Oil microembolism